Ratings by BofA Securities (Tim Anderson)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/10/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Buy (N/A) |
10.13 (9.42) |
-7.01% | Details | |
| 3/3/2025 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2025 | Metsera Inc | MTSR | New Coverage | Buy (N/A) |
29.81 (30.33) |
1.74% | Details | |
| 2/11/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 2/11/2025 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2025 | Johnson & Johnson | JNJ | Maintain | Neutral (N/A) |
|
Details | ||
| 1/15/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2024 | Regeneron Pharma | REGN | New Coverage | Underperform (N/A) |
788.00 (664.96) |
-15.61% | Details | |
| 12/10/2024 | Moderna | MRNA | New Coverage | Underperform (N/A) |
45.65 (33.81) |
-25.94% | Details | |
| 12/10/2024 | Gilead Sciences | GILD | New Coverage | Buy (N/A) |
90.59 (110.23) |
21.68% | Details | |
| 12/10/2024 | Biogen | BIIB | New Coverage | Neutral (N/A) |
156.46 (143.09) |
-8.55% | Details | |
| 12/10/2024 | Amgen | AMGN | New Coverage | Underperform (N/A) |
277.63 (318.65) |
14.78% | Details | |
| 12/10/2024 | Pfizer | PFE | New Coverage | Neutral (N/A) |
26.10 (26.31) |
0.8% | Details | |
| 12/10/2024 | Merck | MRK | New Coverage | Buy (N/A) |
103.79 (94.72) |
-8.74% | Details | |
| 12/10/2024 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
803.58 (822.51) |
2.36% | Details | |
| 12/10/2024 | Johnson & Johnson | JNJ | New Coverage | Neutral (N/A) |
149.60 (164.25) |
9.79% | Details | |
| 12/10/2024 | Bristol-Myers Squibb Co. | BMY | New Coverage | Neutral (N/A) |
58.71 (59.90) |
2.03% | Details | |
| 12/10/2024 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
176.57 (213.85) |
21.11% | Details |
